Hongyun Zhao

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center · ORCID：0009-0004-1986-827X

发表论文 8 篇 · 总被引 63 次 · h-index 4

代表论文

• Consensus on the lung cancer management after third-generation EGFR-TKI resistance (2024 · The Lancet Regional Health - Western Pacific · 被引 27)
• HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype (2024 · Journal for ImmunoTherapy of Cancer · 被引 16)
• Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC). (2025 · Journal of Clinical Oncology · 被引 8)
• Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations. (2025 · Journal of Clinical Oncology · 被引 8)
• Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial (2025 · BMC Medicine · 被引 1)
• Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors. (2024 · Journal of Clinical Oncology · 被引 1)